Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

Background Itch, skin pain, and sleep disturbance are burdensome symptoms in atopic dermatitis (AD) that negatively influence a patient’s quality of life (QoL). Objective To evaluate the impact of baricitinib on patient-reported outcomes (PROs) in adult patients with moderate-to-severe AD, and explo...

Full description

Bibliographic Details
Main Authors: K. Reich, A. M. DeLozier, F. P. Nunes, J. P. Thyssen, L. F. Eichenfield, A. Wollenberg, J. A. Ross Terres, S. D. Watts, Y.-F. Chen, E. L. Simpson, J. I. Silverberg
Format: Article
Language:English
Published: Taylor & Francis Group 2022-04-01
Series:Journal of Dermatological Treatment
Subjects:
atopic dermatitis
eczema
clinical trial
jak inhibitor
Online Access:http://dx.doi.org/10.1080/09546634.2020.1839008

Internet

http://dx.doi.org/10.1080/09546634.2020.1839008

Similar Items